{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T04:27:46Z","timestamp":1782534466021,"version":"3.54.5"},"reference-count":24,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ejinme.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.ejim.2013.11.007","type":"journal-article","created":{"date-parts":[[2013,12,5]],"date-time":"2013-12-05T02:00:19Z","timestamp":1386208819000},"page":"173-176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":76,"title":["Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: An emerging paradigm in diabetic nephropathy"],"prefix":"10.1016","volume":"25","author":[{"given":"Thomas A.","family":"Mavrakanas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Gariani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Yves","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2013.11.007_bb0005","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF00877755","article-title":"\u201cEscape\u201d of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin-converting enzyme inhibitor: implications for therapy","volume":"9","author":"Pitt","year":"1995","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.ejim.2013.11.007_bb0010","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1681\/ASN.2005111196","article-title":"Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats","volume":"17","author":"Han","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ejim.2013.11.007_bb0015","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ejphar.2008.06.019","article-title":"Spironolactone exhibits direct renoprotective effects and inhibits renal renin\u2013angiotensin\u2013aldosterone system in diabetic rats","volume":"589","author":"Taira","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.ejim.2013.11.007_bb0020","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1111\/j.1523-1755.2004.00913.x","article-title":"Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats","volume":"66","author":"Fujisawa","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.ejim.2013.11.007_bb0025","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1210\/en.2006-0944","article-title":"Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus","volume":"47","author":"Guo","year":"2006","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejim.2013.11.007_bb0030","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/ndt\/gfn448","article-title":"Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats","volume":"24","author":"Kang","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ejim.2013.11.007_bb0035","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1159\/000316113","article-title":"Effect of ramipril alone compared to ramipril with eplerenone on diabetic nephropathy in streptozocin-induced diabetic rats","volume":"86","author":"Mavrakanas","year":"2010","journal-title":"Pharmacology"},{"key":"10.1016\/j.ejim.2013.11.007_bb0040","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1111\/j.1523-1755.2005.00756.x","article-title":"Beneficial impacts of spironolactone in diabetic nephropathy","volume":"68","author":"Schjoedt","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.ejim.2013.11.007_bb0045","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.2337\/diacare.28.9.2106","article-title":"Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy","volume":"28","author":"Rossing","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejim.2013.11.007_bb0050","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/sj.ki.5001580","article-title":"Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy","volume":"70","author":"Schjoedt","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.ejim.2013.11.007_bb0055","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1097\/01.hjh.0000249708.44016.5c","article-title":"Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function","volume":"24","author":"Van den Meiracker","year":"2006","journal-title":"J Hypertens"},{"key":"10.1016\/j.ejim.2013.11.007_bb0060","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2215\/CJN.00240106","article-title":"Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes","volume":"1","author":"Epstein","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ejim.2013.11.007_bb0065","doi-asserted-by":"crossref","first-page":"714","DOI":"10.2310\/JIM.0b013e31816d78e9","article-title":"Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind, crossover trial","volume":"56","author":"Saklayen","year":"2008","journal-title":"J Investig Med"},{"key":"10.1016\/j.ejim.2013.11.007_bb0070","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1681\/ASN.2009070737","article-title":"Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy","volume":"20","author":"Mehdi","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ejim.2013.11.007_bb0075","doi-asserted-by":"crossref","first-page":"e184","DOI":"10.1111\/j.1464-5491.2012.03585.x","article-title":"Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study","volume":"29","author":"Nielsen","year":"2012","journal-title":"Diabet Med"},{"key":"10.1016\/j.ejim.2013.11.007_bb0080","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/ki.1989.190","article-title":"Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril","volume":"36","author":"Heeg","year":"1989","journal-title":"Kidney Int"},{"key":"10.1016\/j.ejim.2013.11.007_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1523-1755.2004.00701.x","article-title":"Aldosterone in the development and progression of renal injury","volume":"66","author":"Hollenberg","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.ejim.2013.11.007_bb0090","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/ki.2011.48","article-title":"Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease","volume":"79","author":"Bertocchio","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.ejim.2013.11.007_bb0095","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1161\/01.HYP.0000044937.95080.E9","article-title":"Effectiveness of aldosterone blockade in patients with diabetic nephropathy","volume":"41","author":"Sato","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2013.11.007_bb0100","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0031-6997(25)06820-6","article-title":"Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors","volume":"47","author":"Linz","year":"1995","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.ejim.2013.11.007_bb0105","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2013.11.007_bb0110","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0140-6736(98)01085-X","article-title":"Does quality of reports of randomized trials affect estimates of intervention efficacy reported in meta-analyses?","volume":"352","author":"Moher","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2013.11.007_bb0115","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"ONTARGET Investigators","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2013.11.007_bb0125","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archinte.158.1.26","article-title":"Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry?","volume":"158","author":"Reardon","year":"1998","journal-title":"Arch Intern Med"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620513010005?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620513010005?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T01:53:29Z","timestamp":1746064409000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620513010005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S0953620513010005"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2013.11.007","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: An emerging paradigm in diabetic nephropathy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2013.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}